Biomarkers Market Analysis Report By Type, Services, Application, Disease, Region, Opportunity, And Growth Forecasts, 2030

The global biomarkers market size is expected to reach USD 181.03 billion by 2030, registering a CAGR of 13.3% over the forecast period, according to a new report by Grand View Research, Inc. The rising R&D investments by pharmaceutical and biotechnology companies, increasing number of Contract Research Organizations (CROs), and declining cost of clinical trials in emerging economies are the major driving factors for the industry. In addition, key players leverage various strategies to increase their production capabilities and promote the outreach of their product offerings. In June 2022, Paige announced its collaboration with Janssen to evaluate the potential of an (H&E)-based, (AI)-powered biomarker test, developed by Janssen, to screen for actionable FGFR3 and FGFR2 genomic alterations in patients with bladder cancer.

Biomarkers Market Report Highlights

  • The safety segment held the largest share in 2022 owing to the increased adoption of safety biomarkers in drug discovery and development
  • The efficacy segment will register the fastest growth rate from 2023 to 2030 due to a rise in strategic collaborations for promoting research activities
  • The drug discovery & development segment accounted for the largest share in 2022 due to the extensive R&D efforts taken by leading participants, and the rising adoption of biomarkers in drug discovery
  • The cancer disease segment dominated the industry in 2022. However, the neurological diseases segment is anticipated to record the fastest CAGR over the forecast years
  • Asia Pacific is expected to be the fastest-growing region over the forecast period due to the rising investments by key players and increasing disease prevalence in the region

Gain deeper insights on the market and receive your free copy with TOC now @: Biomarkers Market Report

Biomarkers A.K.A molecular markers or signature molecules are the measures used to perform a clinical assessment such as blood pressure or cholesterol level and are used to monitor and predict health states in individuals or across populations so that appropriate therapeutic intervention can be planned. They may be used to see how well the body responds to a treatment for a disease or condition. It includes pulse and blood pressure through basic chemistries to more complex laboratory tests of blood and other tissues. In drug development, they are used to determine the pharmacogenetic tolerance to pharmaceutical compounds, quantify the disease progression, and identify the prognostic indicators in each patient for end-stage renal disease. They can be categorized as diagnostic biomarkers, staging of disease biomarkers, disease prognosis biomarkers or cancer biomarkers, and biomarkers for monitoring the clinical response to an intervention.

U.S. Biomarkers Market Size By Type
U.S. Biomarkers Market size, by type

The increasing prevalence of chronic diseases like cancer, diabetes, and cardiovascular disorders is anticipated to fuel industry growth. According to the American Cancer Society, in 2022, an estimated 1.9 million new cancer cases were registered in the U.S., accounting for 609,360 deaths. Breast and lung cancers were observed as the most common ones worldwide. In addition, according to a report published in 2020 by the Institute for Health Metrics and Evaluation, cardiovascular diseases cause about 18.9 million deaths annually. Increasing research focused on the identification of new diagnostic biomarkers is fueling the industry’s growth. For instance, in February 2022, Japanese scientists found two new diagnostic tissue biomarkers, PHGDH and TRIM29, indicated for malignant pleural mesothelioma.

These agents can be used to diagnose mesothelioma quickly and help doctors in differentiating between mesothelioma and other cancers. Moreover, in January 2020, a nascent research study published in the Journal of Nuclear Medicine discussed the potential of several breast cancer biomarkers. A notable and easily identifiable imaging biomarker recognized in the study was 18F-FDG PET. Moreover, the COVID-19 pandemic has encouraged the use of biomarkers for facilitating the detection & treatment of the disease. For instance, in March 2021, a new biomarker-based screening device, named Tiger Tech COVID Plus Monitor, was approved by the U.S. FDA.

The device can be used for the identification of biomarkers for COVID-19 and other hypercoagulable & hyperinflammatory conditions in individuals aged 5 years & above. Furthermore, various strategic initiatives undertaken by leading participants are anticipated to cater to demand. For instance, in August 2022, Roche received the U.S. FDA approval for VENTANA MMR RxDx Panel to detect pMMR endometrial cancer patients and dMMR solid tumor patients eligible for treatment with Merck’s immunotherapy Keytruda. This approval for the VENTANA MMR RxDx Panel is a label expansion of the company’s recent on-market panel. Also, in December 2021, Siemens Healthineers partnered with Freenome to identify novel suitable markers for the detection of early breast cancer to expand its existing imaging technologies.

Biomarkers Market Insights By Region

North America led the global industry due to the high disease burden, increased consumer awareness about biomarkers, supportive government initiatives, technological advancements, and improvements in healthcare infrastructure. Asia Pacific, on the other hand, is anticipated to register the fastest growth rate during the projected period. Factors, such as a surge in funding for biomarkers discovery, high prevalence of cancer, rising research initiatives, and low cost of clinical trials in developing nations are expected to support regional growth. In addition, an increase in funding for biotech and pharma companies, a rise in the number of CROs, and an increasing application scope of biomarkers are expected to facilitate regional market growth during the projected period.

Competitive Analysis By Major Companies

Key players are adopting strategies, such as new product development, merger & acquisition, and partnership, to increase their industry share. Some of the prominent players in the global biomarkers market include:

  • Hoffmann-La Roche Ltd.
  • Abbott
  • Epigenomics AG
  • General Electric
  • Johnson & Johnson Services, Inc.
  • Thermo Fisher Scientific Inc.

For More Details or Sample Copy please visit link @: https://www.grandviewresearch.com/industry-analysis/biomarkers-industry/request/rs5

Biomarkers Market Segmentation

Grand View Research has segmented the global biomarkers market based on type, application, disease, and region:

  • Biomarkers Type Outlook (Revenue, USD Billion, 2018 – 2030)
  • Biomarkers Application Outlook (Revenue, USD Billion, 2018 – 2030)
  • Biomarkers Disease Outlook (Revenue, USD Billion, 2018 – 2030)
  • Biomarkers Regional Outlook (Revenue, USD Billion, 2018 – 2030)
  • List of Key Players of Biomarkers Market

Research Methodology

We employ a comprehensive and iterative research methodology focused on minimizing deviance in order to provide the most accurate estimates and forecasts possible. We utilize a combination of bottom-up and top-down approaches for segmenting and estimating quantitative aspects of the market. Data is continuously filtered to ensure that only validated and authenticated sources are considered. In addition, data is also mined from a host of reports in our repository, as well as a number of reputed paid databases. Our market estimates and forecasts are derived through simulation models. A unique model is created and customized for each study. Gathered information for market dynamics, technology landscape, application development, and pricing trends are fed into the model and analyzed simultaneously.

For Customized reports or Special Pricing please visit @: https://www.grandviewresearch.com/special-pricing/70/rfsp2

About Grand View Research

Grand View Research provides syndicated as well as customized research reports and consulting services on 46 industries across 25 major countries worldwide. This U.S. based market research and consulting company is registered in California and headquartered in San Francisco. Comprising over 425 analysts and consultants, the company adds 1200+ market research reports to its extensive database each year. Supported by an interactive market intelligence platform, the team at Grand View Research guides Fortune 500 companies and prominent academic institutes in comprehending the global and regional business environment and carefully identifying future opportunities.

 

Contact:

Grand View Research, Inc.

Phone: 1-415-349-0058

Toll-Free: 1-888-202-9519

Email: [email protected]

Web: https://www.grandviewresearch.com